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ABSTRACT
Background This paper summarises a series of presentations on telemedicine 
given at a UK eHealth Week conference session in 2016. The formal evidence base 
for telemedicine is equivocal, but practical experience suggests that implementa-
tions of technology that support telemedicine initiatives can result in improved 
patient outcomes, better patient and carer experience and reduced expenditure.
Objective To answer the questions ‘Is an investment in telemedicine worth it’? 
and ‘How do I make a telemedicine implementation work’?
Methods Summary of systematic review evidence and an illustrative case study. 
Discussion of implications for industry and policy.
Results  Realisation of telemedicine benefits is much less to do with the technol-
ogy itself and much more around the context of the implementing organisation and 
its ability to implement.
Conclusion We recommend that local organisations consider deployment of 
telemedicine initiatives but with a greater awareness of the growing body of imple-
mentation best practice. We also recommend, for the National Health Service, that 
the centre takes a greater role in the collation and dissemination of best practice 
to support successful implementations of telemedicine and other health informatics 
initiatives.
Keywords: telecare, telemedicine, telehealth, health informatics, digital health, 
health technology, technology policy
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INTRODUCTION
As part of a recent UK eHealth Week conference, BCS Health 
& Care hosted a session on telemedicine. This 90-minutes 
series of presentations was intended to give delegate 
answers to the questions ‘Is an investment in telemedicine 
worth it’? and ‘How do I make a telemedicine implementa-
tion work’? To answer these questions, the session was 
constructed to include a summary of the current evidence, a 
demonstration of recent case studies with real examples of 
learning, the policy position and the role industry can play in 
ensuring success. 
Contributors to the session who had first-hand experience 
of implementing telemedicine interventions found it difficult to 
reconcile their experience with the findings of the Cochrane 
systematic review on the subject. The session was initiated to 
explore this apparent contradiction.
This paper is a summary of that session to support local 
decision makers investigating telemedicine. We hope that it 
gives health and care informaticians, clinicians and commis-
sioners a reason to consider informatics innovations even 
when a systematic review appears to demonstrate equivocal 
benefit.
THE EVIDENCE BASE
Recent decades have seen a revolution in the field of tech-
nology, which has changed the way we interact with other 
people and also how we seek and exchange information. 
Importantly, information and communication technologies 
(ICTs) may also potentially revolutionise the delivery and 
organisation of healthcare in many different ways: improv-
ing health outcomes, reducing costs and increasing access, 
especially in underserved and rural areas and in low-income 
countries. However, it is important that the implementation of 
technology be accompanied by thorough evaluation that sup-
ports its effectiveness in specific clinical situations. 
The Cochrane Effective Practice and Organisation of Care 
group conducted a systematic review of the literature to 
determine the effects of interactive telemedicine on profes-
sional practice and healthcare outcomes,1 when compared 
with traditional face-to-face delivery of care. The review, pub-
lished in the Cochrane library in September 2015, included 
93 randomised controlled trials (RCTs), in which telemedicine 
was used in direct patient care, either as a supplement, or 
as a substitute for usual care and assessed the effective-
ness, acceptability and costs of interactive telemedicine. It 
did not assess the reasons why a telemedicine intervention 
may have demonstrated, or failed to demonstrate, significant 
benefits. 
A majority of the included studies targeted patients with 
chronic conditions like heart failure and diabetes. In these 
studies, telemedicine was mainly used for remote monitoring 
of the condition, to enable prompt treatment and advice. In 
other studies, telemedicine was used to provide treatment, 
rehabilitation, education and advice for self-management or 
specialist consultations, to give some examples. For each 
condition,  the  review  pooled  outcome  data  that were  suffi-
ciently homogeneous. This limited the pooling of results to 
heart failure and diabetes outcomes. 
The  review findings  indicate  that  the use of  telemedicine 
in the management of heart failure may lead to similar health 
outcomes as face-to-face or telephone delivery of care. 
There is also evidence that telemedicine can improve the 
control of blood glucose in people with diabetes. The cost 
to health services, the acceptability by patients and health-
care professionals and the effects on professional practice 
are not clear due to limited data reported for these outcomes. 
Videoconferencing studies recruiting participants requir-
ing mental health services, or specialist consultations for a 
dermatological condition reported no differences between 
groups. There was some evidence that remote monitoring 
could improve blood pressure control in participants with 
hypertension,  while  findings  from  the  other  studies  were 
inconsistent. 
There are a couple of limitations with the review to con-
sider. First, the search cut-off may have resulted in the 
inclusion of outdated telemedicine systems. Second, it was 
impossible for the investigators to keep up with the large 
volume of trials continuously being published, wherefore a 
large number of potentially eligible studies had to be listed 
as awaiting assessment at the date of publication. Third, by 
including very small studies, the timeliness of the publication 
was hampered.2
Very few of the included studies contained data on organ-
isational factors suggested to be important3 when new tele-
medicine programs are initiated, for example, the readiness 
of healthcare professionals to change their practice, the 
preparedness of the healthcare organisation and the time 
allowed for integration of telemedicine into a local health 
system. 
Although there are gaps in our knowledge of what works 
in which conditions, there is reason for optimism. The large 
number of recently published and ongoing studies will add to 
the current evidence base. The increasing cell-phone cover-
age,4 especially in low-income countries, and the fact that the 
next generation of older people will most likely be much more 
comfortable using ICT, adds to the optimism surrounding the 
future use of telemedicine. 
THE ART OF THE POSSIBLE – EXPERIENCES 
FROM AIREDALE
Nearly 400,000 older people live in care homes in the United 
Kingdom, nearly 20% of whom are aged 85 and over. Most 
have complex health needs, including multiple long-term con-
ditions, significant disability and advanced frailty. Collectively, 
they have high rates of both necessary and avoidable hospi-
tal admissions.5
Care provided to this complex cohort of people is often 
fragmented and services vary widely in standard, with high 
staff turnover and limited support from the wider health sys-
tem. The Digital Care Hub at Airedale National Health Service 
(NHS) Foundation Trust (NHSFT) was opened in September 
Journal of Innovation in Health Informatics Vol 25, No 1 (2018)
Freed et al. Telemedicine: is it really worth it? A perspective from evidence and experience 16
2011 to provide 24/7 clinical video assessment to support staff 
in caring for these residents as well as other patient groups. 
Having used telemedicine to deliver face-to-face consulta-
tions for patients in their own homes, the care home model 
was developed as it was thought to be more cost-effective, 
led by nurses and supported by the specialists in the acute 
trust. Airedale NHSFT had already been successfully provid-
ing remote outpatient consultations to prisoners since 2007, 
which had led to the prevention of unnecessary transport of 
offenders to hospital and had greatly reduced both the bed 
watch and escort budgets in those prisons using the service.
Discussions with nurses undertaking consultations indi-
cated that they felt the three key aspects required for the tele-
medicine service to function well were: access to a clinical 
assessor; access to electronic patient records and the ability 
to  clearly  see  the patient  using a high-definition  video  link. 
The services at Airedale’s Digital Care Hub have developed 
to include remote general practitioner (GP) triage, where care 
homes call the hub to assess the residents rather than call-
ing the GP; the Gold Line, a telephone and video service to 
patients on the Gold Standards Framework6 thought to be in 
their last year of life; an Intermediate Care Hub, where health 
and social care staff work together to provide patients with 
the most appropriate service for their needs including a step-
up and step-down pathway for frail elderly patients, before 
making the decision that they may need to reside in a care 
facility; and a complex care team that support those service 
users in the community with the highest reliance on health 
and social care. Patients and their carers have access to a 
clinical team 24/7/365 which aims to promote their wellbe-
ing, encourage self-care and enhance the use of informal 
support mechanisms, primary care and community services. 
Operational and clinical pathways have been implemented, 
working closely with community and primary care teams, to 
enable  early  intervention  and  timely  identification  and  sup-
port for patients, particularly those residing in care homes 
leading to a reduction in inappropriate attendance at the 
emergency department (ED) or acute admission to hospital.7 
The use of remote video consultation has also demonstrated 
a reduction in GP visits (particularly out of hours), and the 
need for numerous community team and District Nurse visits 
(Vanguard evaluation report in preparation).
It took a number of years to establish the digital care hub at 
Airedale NHSFT as commissioners were reluctant to contract 
a service without a strong evidence base and a critical mass 
of service users was necessary to develop this. A number of 
Clinical Commissioning Groups (CCGs) wanted to pilot the 
service in a small number of care homes, but this left the 
majority continuing to send residents to ED as they always 
had, making a significant outcome difficult to demonstrate.8
Clinicians were slow to adapt to this new way of working 
and questioned the governance around remote assessment 
which led to a nurse led service being developed which has 
proven to be both more cost effective and more robust across 
a 24/7 provision. Some care homes – particularly indepen-
dent providers – needed to be persuaded that the hub would 
be beneficial for them. Airedale addressed this challenge by 
working with each care home to understand their difficulties 
and show how access to the hub staff could help them to 
better deal with their own problems. For example, the hub 
supports the staff to deliver better care to their residents, 
making the NHS Care Quality Commission (CQC) inspection 
regime easier and more transparent, and increasing staff’s 
confidence and skills.
There were few technology providers available for the 
development phase. Airedale has a joint venture partner – 
Involve – which supplies and installs a secure video link to 
the hub via a secure N3 (NHS network) platform. Each care 
home or patient needs to have access to at least one laptop 
and a reliable internet or 3G/4G connection and they also 
have access to a 24/7 helpline for technical support. Cisco 
webcams, software and infrastructure are in use in Airedale, 
but any HD 1080p (hardware encoder) camera would be 
suitable. The 24/7 technical support helpline is provided by 
Involve.
Despite numerous visits to the hub by interested trusts and 
commissioners, there are few other facilities set up across 
the country. This may be due in part to the financial  invest-
ment required to deploy the infrastructure but also to the 24/7 
staffing  requirement and culture change needed  to change 
from face to face to remote clinical assessment.
THE ROLE OF INDUSTRY – PRODUCTS  
AND SERVICES
Telemedicine and other products and services that enable 
medical/social care functions to be performed remotely 
are dependent on several technologies. These include the 
following: 
 • computing power, 
 • advanced analytics (software), 
 • intuitive device interfaces,
 • standardised connectivity and communication 
formats, 
 • sensors and other point of care devices,
 • large data transfers, and
 • secure storage, retrieval and display of data. 
Processing power and speed can be measured, but there 
are few objective ways of tracking improvements in the other 
technology elements. However, telecommunication speed is 
a particularly important factor for facilitating remote services; 
individual developments, especially in mobile technologies, 
are  arguably  the  most  significant  motivators  for  support-
ing innovation, especially for people outside the hospital 
environment. 
It may be apparent that new technologies and tele-services 
quickly follow each improvement in telecommunication band-
width. The half-life of each new device must also reduce, 
along with opportunities to demonstrate, from a clinical per-
spective,  successful  outcomes  such  as  efficacy  and  value 
for money. From a commercial perspective, it impacts the 
likelihood of achieving an acceptable return on investment, 
compromising incentives to innovate and preventing the 
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transformation of service delivery needed to make health 
service more efficient, while reducing the demand.
There is a need to streamline processes of acceptance 
for introducing, and mainstreaming, new products and pro-
cesses, but without compromising the need for evidence that 
both clinicians and the service commissioners rely on. The 
gold standard randomised control trial is inappropriate for 
remote and self-monitoring from a commercial point of view 
because
 • most remote monitoring solutions are produced by 
small to medium enterprise (SMEs) who simply do not 
have the resources,
 • many solutions support people that are without a 
formal diagnosis of an illness, so compromising timely 
participant identification,
 • the market for many products will be small making it 
difficult to recruit sufficient numbers of participants,
 • individual technologies are not designed to replace 
medical interventions, but are usually proposed as 
components in care plans, making their success 
dependent on other parts of the system that are 
difficult to control, and
 • they often involve lifestyle changes making 
adherence to trial protocols difficult over the long 
periods required to confirm behavioural change and 
outcomes.
In order to support a more rapid route to market for remote 
monitoring and management strategies, service/product 
providers need stronger links to both the clinicians who can 
champion their products and to the service commissioners. 
All stakeholders need access to current evidence and usage 
data. Much of the evidence will be derived from end-users 
(i.e. patients) rather than from clinicians, which needs to 
be collected quickly and managed in a way that is trusted. 
As access to community equipment and telecare services 
becomes more restricted, giving way to more individually 
funded schemes (personal budget), the public will also need 
reliable and impartial advice to avoid them buying the devices 
that are low cost but lacking in the usage evidence that would 
confirm appropriateness and safety. 
THE ROLE OF POLICY – THE IMPACT  
OF PAYMENTS
The nationally set prices and rules for local pricing that gov-
ern how money flows between commissioners and providers 
of NHS funded services should not be a barrier to innovation, 
including the effective use of telemedicine. Unfortunately, in 
practice, it is often felt to be just that, even if the rules them-
selves  are  flexible  to  at  least  accommodate  it  and  at  best 
enable it.
The national prices set for the Healthcare Resource Group 
(HRG) – standardised bundles of types of clinical activity – 
are designed to act as a benchmark to beat. This should, in 
principle, enable and incentivise cost-effective innovations. 
However, often a particular set of resource and procedure 
codes need to get ticked for care to qualify for payment under 
the HRG, so the HRGs are either not available or relevant for 
new innovative ways of delivering care such as telemedicine. 
There are two main ways in which the prices and rules at 
the moment accommodate and enable innovation:
 • The local pricing rules, applied where there are 
no national prices or HRGs, are built on three 
principles that support innovation. The local 
payment approaches need to:9 1) be in the best 
interest of patients, 2) promote transparency and 
improve accountability and 3) be developed through 
constructive engagement.
 • The payment rules also give explicit permission 
to agree to vary from the nationally set prices and 
HRGs. The locally agreed approach needs to satisfy 
the above principles, but there is no approval process 
to go through.
Using the local pricing rules can mean providers and com-
missioners need to put in extra effort. Developing a set of 
national prices for telemedicine would not be an effective 
solution to reduce the local burden. There are a multitude 
of ways and circumstances where telemedicine is used, and 
new ones are being trialled and implemented constantly. 
Prices would likely be out of date even before they were 
ready  to  be  published.  Worse  prices  for  specific  ways  of 
doing telemedicine could then act to standardise provision 
before the best solutions have been discovered.
Instead, NHS Improvement is working to make the payment 
system more supportive of innovation and service reforms in 
all their forms. That includes work towards better cost, qual-
ity and activity data as well as new payment approaches 
focused on value to support new models of care.10 Paying 
provider groups that use capitation linked to outcomes (rather 
than activity) supports improvement in a number of areas:
 • Predictability of upfront payment gives providers 
stability to plan and implement changes.
 • Accountability and flexibility to meet the care 
needs of the population, coordinating across 
traditional boundaries, provides greater opportunities 
for changing care delivery across full pathways 
without immediate top line revenue impacts from 
changing types and amounts of activity.
 • Risk transfer that rewards providers for doing the 
right thing, without a detailed specification of how to 
deliver care.
DISCUSSION
On the face of it, the evidence is confusing. Organisations 
small and large are clearly achieving significant benefit from 
using technology to support the modernisation of care deliv-
ery, Airedale being the best single example quoted. On the 
other hand, the evidence from RCTs is at best mixed.
Could it be that the problem is actually with the RCTs? 
They are designed as  they are  to check on  the efficacy of 
medicines which have very different characteristics:
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 • Many medicines are affected by the genetics of the 
person taking them;
 • Medicines are clearly dependent on whether they are 
taken as prescribed (in the world, 50% are not, for a 
wide variety of reasons);
 • As medicine relies mainly on chemical reactions, it 
is typically relatively independent of care pathway 
(within limits, of course);
 • Medicines need regular replenishment;
 • Telemedicine on the other hand is not genetically 
dependent;
 • Failure of a user to send in vital signs, readings or 
other interactions is immediately evident, enabling 
remedial action to be taken;
 • Most importantly, telemedicine delivers virtually all 
its benefits by enabling new models of care and so 
if constrained by an RCT that looks only at adding 
telemedicine without also allowing a change in care 
pathway is almost guaranteed to show little if any 
benefit – possibly even a net cost.
As a result of the above, perhaps it is now time to look at 
other ways of measuring the benefits of  telemedicine using 
engineering principles – as Jeremy Wyatt has commented 
‘no one does an RCT of bridges’, yet most of them deliver as 
planned a calculated level of benefit.
The Cochrane systematic review, and several studies 
published since (and notably the Airedale experience sum-
marised here) demonstrate that telemedicine can provide 
significant  benefits  –  to  patient  and  carer  experience,  to 
support improved health outcomes and to reduce costs. Yet 
these benefits are not guaranteed.
While  the  technology  can  provide  benefits,  it  is  the  con-
text in which the technology is implemented and the skill with 
which the implementation is conducted that realises benefits. 
CONCLUSION
To answer the question posed in our title, the evidence 
demonstrates that telemedicine as a technology is worth it, 
although return on investment varies with the care pathway 
and, most significantly, in the ability of the team to implement 
effectively. However, given the huge dependence on context, 
including ability to implement, readiness of staff and patients 
to change and clear leadership, our conclusion is that tele-
medicine, and by extension health technology, will always be 
dogged by equivocal results because of the huge impact of 
context, outwith anything to do with the technology per se. 
If that conclusion is accepted, two recommendations fall 
out. First, local implementers must concentrate on the sci-
ence of implementation – the things to do and things to avoid, 
learning from others, both successful and unsuccessful. 
Examples of places to find these answers will be from authors 
of peer-reviewed papers, discussion forums [e.g. the Digital 
Health  Intelligence  Chief  Information  Officer  (CIO)  forum, 
the Digital Health & Care Alliance or the CHAIN network] 
and professional champions. Second, policy makers and 
national funders should concentrate on making implementa-
tion advice more accessible and consumable through custom 
advice services, passive resources (such as the NHS Digital 
website) and by making resources available for free through 
other bodies, for example, the Federation of Informatics 
Professionals website or the e-Learning for Health portal.
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